Why Retatrutide Is the Hardest Peptide to Verify: An Analytical Breakdown
Right now, across the country, people have freezers full of a drug that technically doesn’t exist yet. According to a recent investigation by the New York Times, an estimated 15 pounds of retatrutide—perhaps hundreds of thousands of doses—flowed into the U.S. in just the first four months of 2026. It’s being bought with Bitcoin, coordinated […]
The Gray Market’s Crypto Pipeline: From Fentanyl Precursors to Peptides
A bombshell Chainalysis report reveals the 00M crypto pipeline fueling gray-market peptides — and the alarming connection to fentanyl precursor manufacturers. Here’s what the collapse of independent testing means for consumer safety.
What’s Actually In Your Cream? The 5 Tests Every Topical Should Pass
It was supposed to be a simple, multi-symptom eczema cream. Sold nationwide at major retailers and on Amazon, the product sat on the shelves of thousands of American homes. Then came the recall. In May 2026, the FDA announced that the cream had been contaminated with Staphylococcus aureus—a bacteria capable of causing severe, life-threatening infections, […]
When States Draw the Line: The New Era of State-Level Peptide Enforcement
When States Draw the Line: The New Era of State-Level Peptide Enforcement and the Critical Need for Analytical Verification Introduction: The Illusion of the Grey Market Workaround For the past several years, the rapidly expanding peptide therapy market has operated under a fragile regulatory truce. Clinicians, medical spas, and wellness centers seeking to offer cutting-edge […]
The Relabeling Problem: When Your Peptide Vial Lies About Its Origin
Two major legal actions have exposed a massive vulnerability in the peptide supply chain. A Chinese manufacturer on the FDA Green List was caught relabeling semaglutide, and a Utah doctor was indicted for selling relabeled Chinese peptides to 200+ patients.
The 503B Loophole Closes: Why the FDA is Moving to Exclude GLP-1s from Bulk Compounding
On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. As legitimate compounding pathways narrow, independent analytical testing becomes the only reliable defense against substandard supply.
98% Pure. So What Is the Other 2%?
98% pure is the most common claim in the peptide industry. But what is the other 2%? A peptide impurity investigation.
The “Wild West” Week: What 6 Major Outlets Got Right — and Wrong — About Peptide Quality
Six major publications ran peptide safety stories in five days. We read all of them, traced their claims back to the data, and found a more complicated picture than any single headline captured.
The “Wild West” Week: What 6 Major Outlets Got Right — and Wrong — About Peptide Quality
Six major publications ran peptide safety stories in five days. We read all of them, traced their claims back to the data, and found a more complicated picture than any single headline captured.